NZ183001A - 3-dimethylamin opropyl-3-phenyl-benzo(c)furans,and pharmaceutical compositions - Google Patents

3-dimethylamin opropyl-3-phenyl-benzo(c)furans,and pharmaceutical compositions

Info

Publication number
NZ183001A
NZ183001A NZ183001A NZ18300177A NZ183001A NZ 183001 A NZ183001 A NZ 183001A NZ 183001 A NZ183001 A NZ 183001A NZ 18300177 A NZ18300177 A NZ 18300177A NZ 183001 A NZ183001 A NZ 183001A
Authority
NZ
New Zealand
Prior art keywords
dimethylaminopropyl
phthalancarbonitrile
compound according
compound
formula
Prior art date
Application number
NZ183001A
Other languages
English (en)
Inventor
K Bogeso
A Toft
Original Assignee
Kefalas As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9722860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ183001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kefalas As filed Critical Kefalas As
Publication of NZ183001A publication Critical patent/NZ183001A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NZ183001A 1976-01-14 1977-01-06 3-dimethylamin opropyl-3-phenyl-benzo(c)furans,and pharmaceutical compositions NZ183001A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1486/76A GB1526331A (en) 1976-01-14 1976-01-14 Phthalanes

Publications (1)

Publication Number Publication Date
NZ183001A true NZ183001A (en) 1978-06-02

Family

ID=9722860

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ183001A NZ183001A (en) 1976-01-14 1977-01-06 3-dimethylamin opropyl-3-phenyl-benzo(c)furans,and pharmaceutical compositions

Country Status (19)

Country Link
US (1) US4136193A (en:Method)
JP (1) JPS52105162A (en:Method)
AT (1) AT359488B (en:Method)
AU (1) AU509445B2 (en:Method)
BE (1) BE850401A (en:Method)
CA (1) CA1094087A (en:Method)
CH (3) CH626886A5 (en:Method)
DE (1) DE2657013C2 (en:Method)
DK (1) DK143275C (en:Method)
ES (1) ES454980A1 (en:Method)
FI (1) FI63754C (en:Method)
FR (1) FR2338271A1 (en:Method)
GB (1) GB1526331A (en:Method)
IE (1) IE44055B1 (en:Method)
NL (2) NL192451C (en:Method)
NO (2) NO147243C (en:Method)
NZ (1) NZ183001A (en:Method)
SE (1) SE429551B (en:Method)
ZA (1) ZA7757B (en:Method)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602035A (en) * 1983-12-07 1986-07-22 Hoechst-Roussel Pharmaceuticals Inc. Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
PT759299E (pt) * 1995-08-16 2000-09-29 Lilly Co Eli Potenciacao da resposta de serotonina
PT1015416E (pt) * 1997-07-08 2002-03-28 Lundbeck & Co As H Metodo para a producao de citalopram
UA62985C2 (en) * 1997-11-10 2004-01-15 Lunnbeck As H A method for the preparation of citalopram
CN1286687A (zh) * 1997-11-11 2001-03-07 H·隆德贝克有限公司 制备西酞普兰的方法
JP3892667B2 (ja) 1998-10-20 2007-03-14 ハー・ルンドベック・アクチエゼルスカベット シタロプラムの製造方法
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
KR20010081071A (ko) 1998-12-08 2001-08-25 피터슨 존 메이달 벤조푸란 유도체, 그것들의 제조 및 사용
AU764161B2 (en) 1998-12-23 2003-08-14 H. Lundbeck A/S Method for the preparation of 5-cyanophthalide
AR022329A1 (es) 1999-01-29 2002-09-04 Lundbeck & Co As H Metodo para la preparacion de 5-cianoftalida
WO1999030548A2 (en) * 1999-04-14 1999-06-24 H. Lundbeck A/S Method for the preparation of citalopram
ITMI991579A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
ITMI991486A1 (it) * 1999-07-06 2001-01-06 Vis Farmaceutici S P A Processo per la sintesi di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
AU742554B2 (en) * 1999-10-25 2002-01-03 H. Lundbeck A/S Method for the preparation of citalopram
SI1298124T1 (sl) 1999-10-25 2007-08-31 Lundbeck & Co As H Postopek za pripravo citaloprama
AR026063A1 (es) 1999-11-01 2002-12-26 Lundbeck & Co As H Metodo para la preparacion de 5-carboxiftalida.
US6310222B1 (en) 1999-11-01 2001-10-30 Sumika Fine Chemicals Co., Ltd. Production method of 5-phthalancarbonitrile compound, intermediate therefor and production method of the intermediate
EA004742B1 (ru) * 1999-12-28 2004-08-26 Х.Лундбекк А/С Способ получения циталопрама
SK11052002A3 (sk) * 1999-12-30 2003-01-09 H. Lundbeck A/S Spôsob prípravy medziproduktu pri príprave citalopramu
EA005134B1 (ru) * 2000-01-14 2004-12-30 Х.Лундбекк А/С Способ получения 5-цианофталида
US6433196B1 (en) 2000-02-17 2002-08-13 Sumika Fine Chemicals Co., Ltd. Production method of citalopram, intermediate therefor and production method of the intermediate
FR2805812A1 (fr) * 2000-02-24 2001-09-07 Lundbeck & Co As H Procede de preparation du citalopram
IES20010143A2 (en) * 2000-02-24 2001-07-25 Lundbeck & Co As H Method for the preparation of citalopram
IES20010157A2 (en) * 2000-03-03 2002-03-06 Lundbeck & Co As H Method for the preparation of citalopram
GB0005477D0 (en) 2000-03-07 2000-04-26 Resolution Chemicals Limited Process for the preparation of citalopram
SK14522002A3 (sk) * 2000-03-13 2003-03-04 H. Lundbeck A/S Spôsob prípravy citalopramu a citalopram pripravený týmto spôsobom
SK14602002A3 (sk) * 2000-03-13 2003-02-04 H. Lundbeck A/S Spôsob výroby citalopramu a medziprodukty
NL1017500C1 (nl) 2000-03-13 2001-04-26 Lundbeck & Co As H Werkwijze voor de bereiding van Citalopram.
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
IL151488A0 (en) 2000-03-14 2003-04-10 Lundbeck & Co As H Method for the preparation of citalopram
AT5093U1 (de) * 2000-03-16 2002-03-25 Lundbeck & Co As H Verfahren zur herstellung von
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
US6977306B2 (en) 2000-05-02 2005-12-20 Sumitomo Chemical Company, Limited Citalopram hydrobromide crystal and method for crystallization thereof
KR100821912B1 (ko) * 2000-05-12 2008-04-16 하. 룬트벡 아크티에 셀스카브 시탈로프람의 제조 방법
AR032455A1 (es) 2000-05-12 2003-11-12 Lundbeck & Co As H Metodo para la preparacion de citalopram, un intermediario empleado en el metodo, un metodo para la preparacion del intermediario empleado en el metodo y composicion farmaceutica antidepresiva
BR0106976A (pt) * 2000-07-06 2002-07-23 Lundbeck & Co As H Método para a preparação de citalopram
AU8174001A (en) * 2000-07-21 2002-02-05 Lundbeck & Co As H Novel compounds and their use as glycine transport inhibitors
IS6021A (is) * 2000-08-10 2001-10-20 H. Lundbeck A/S Lyfjasamsetningar sem innihalda sítalópram
FI20011621L (fi) * 2000-08-18 2002-02-19 Lundbeck & Co As H Menetelmä sitalopraamin valmistamiseksi
US20030232881A1 (en) * 2000-10-27 2003-12-18 H. Lundbeck A/S Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
US20030109577A1 (en) * 2000-10-27 2003-06-12 Ken Liljegren Pharmaceutical composition containing citalopram
IT1319686B1 (it) * 2000-12-12 2003-10-23 C D Farmasint S R L Procedimento di preparazione di citalopram.
SK286283B6 (sk) * 2000-12-22 2008-06-06 H. Lundbeck A/S Spôsob výroby čisteného citalopramu
MXPA01013336A (es) * 2000-12-28 2002-07-09 Lundbeck & Co As H Proceso para la preparacion de citalopram puro.
DE10112828C1 (de) * 2000-12-28 2002-11-21 Lundbeck & Co As H Verfahren zur Herstellung von Citalopram
DE10164725B4 (de) * 2000-12-28 2004-08-26 H. Lundbeck A/S Verfahren zur Herstellung von gereinigtem Citalopram
AU2001100195B4 (en) * 2001-01-05 2001-12-20 H Lundbeck As Pharmaceutical composition containing citalopram.
EP1355897A1 (en) * 2001-01-30 2003-10-29 Orion Corporation Fermion Process for the preparation of 1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile
JP2004529883A (ja) * 2001-02-22 2004-09-30 ナトコ ファーマ リミテッド シタロプラムの調製方法
GB0105627D0 (en) * 2001-03-07 2001-04-25 Cipla Ltd Preparation of phthalanes
WO2002072565A1 (en) * 2001-03-09 2002-09-19 Ranbaxy Laboratories Limited Process for the preparation of citalopram
US20040198809A1 (en) * 2001-05-01 2004-10-07 Connie Sanchez Use of enantiomeric pure escitalopram
BG65271B1 (bg) * 2001-06-18 2007-11-30 H. Lundbeck A/S Метод за получаване на циталопрам
AR034759A1 (es) * 2001-07-13 2004-03-17 Lundbeck & Co As H Metodo para la preparacion de escitalopram
IN192057B (en:Method) * 2001-07-19 2004-02-14 Ranbaxy Lab Ltd
RS8304A (en) 2001-07-31 2006-12-15 H.Lundbeck A/S. Crystalline composition containing escitalopram
EP1288211A1 (en) * 2001-08-28 2003-03-05 Sekhsaria Chemicals Ltd. Improved process for the manufacture of citalopram hydrobromide from 5-bromophthalide
US6967259B2 (en) * 2001-09-24 2005-11-22 Pharmachem Technologies Limited Process for the preparation of Citalopram intermediate
EP1434763B1 (en) * 2001-10-12 2018-01-17 Azevan Pharmaceuticals, Inc. Beta-lactamyl vasopressin v1a antagonists
IN192863B (en:Method) * 2001-11-13 2004-05-22 Ranbaxy Lab Ltd
IS7239A (is) * 2001-12-14 2004-04-29 H. Lundbeck A/S Aðferð til framleiðslu á essítalóprami
AU2003222435A1 (en) * 2002-01-07 2003-07-24 Sun Pharmaceutical Industries Limited Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
GB0204607D0 (en) * 2002-02-27 2002-04-10 Matrix Lab Ltd Process
GB2387844B (en) * 2002-02-27 2005-05-11 Matrix Lab Ltd Separation of impurities from a crude mixture of citalopram
GB2385848A (en) * 2002-02-27 2003-09-03 Cipla Ltd Citalopram salts
EP1346989A1 (en) * 2002-03-21 2003-09-24 Jubilant Organosys Limited Improved process for the preparation of citalopram and its hydrobromide
TWI332938B (en) * 2002-03-27 2010-11-11 Bando Chemical Ind Novel 1,3,5-tris(arylamino)benzenes
CA2381341A1 (en) * 2002-04-09 2003-10-09 Torcan Chemical Ltd. Process and intermediates for preparing escitalopram
FI20021421A0 (fi) * 2002-07-30 2002-07-30 Orion Corp Fermion Valmistusmenetelmä
TWI306846B (en) * 2002-08-12 2009-03-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
AU2002330730A1 (en) * 2002-08-14 2004-03-03 Natco Pharma Limited Process for the preparation of high purity citalopram and its pharmaceutically acceptable salts
GB2385051B (en) * 2002-08-29 2003-12-24 Max India Ltd Improved process for the preparation of 5-substituted-1 (4-fluorophenyl)-1,3-dihydro isobenzofurans
US6812355B2 (en) 2002-10-22 2004-11-02 Sekhsaria Chemicals Limited Process for the manufacture of citalopram hydrobromide from 5-bromophthalide
MEP5808A (xx) * 2002-12-23 2010-02-10 Lundbeck & Co As H Ecitalopram bromhidrat i postupak za njegovo pripremanje
US20050137255A1 (en) * 2002-12-23 2005-06-23 H. Lundbeck A/S Crystalline escitalopram hydrobromide and methods for preparing the same
AU2003242990A1 (en) * 2003-01-17 2004-08-13 Pulla Reddy Muddasani Processes for the preparation of escitalopram and its precursor
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc METHOD AND COMPOSITION FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
ITMI20030479A1 (it) * 2003-03-13 2004-09-14 Adorkem Technology S P A Procedimento per la preparazione di un ciano-isobenzofurano.
EP1486492A3 (en) * 2003-06-10 2005-02-23 Sun Pharmaceuticals Industries Ltd. A process for hydrogenolysis of [1-(3-dimethylamino)propyl)]-1-(4-fluorophenyl)-1,3-dihydro-5-halo-isobenzofuran.
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
GB0317475D0 (en) * 2003-07-25 2003-08-27 Meditab Specialities Pvt Ltd Product
ITFI20030202A1 (it) * 2003-07-28 2005-01-29 Synteco Spa Processo per la preparazione di derivati del
SI1668014T1 (sl) * 2003-09-17 2009-06-30 Janssen Pharmaceutica Nv Kondenzirane heterociklične spojine kot modulatorji serotoninskih receptorjev
EP1678122A4 (en) * 2003-10-28 2007-05-23 Wockhardt Ltd IMPROVED PROCESS FOR THE PREPARATION OF CITALOPRAM HYDROBROMIDE
DE60300502T2 (de) * 2003-10-28 2006-02-23 Adorkem Technology S.P.A., Costa Volpino Verfahren zur Herstellung von Citalopram
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2547639A1 (en) * 2003-12-02 2005-06-16 B&B Beheer Nv Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists
US20050176680A1 (en) 2003-12-11 2005-08-11 Sepracor, Inc. Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
CN100569765C (zh) * 2003-12-19 2009-12-16 杭州民生药业集团有限公司 西酞普兰中间体晶体碱
TWI339651B (en) * 2004-02-12 2011-04-01 Lundbeck & Co As H Method for the separation of intermediates which may be used for the preparation of escitalopram
EP1723133A1 (en) * 2004-02-16 2006-11-22 Jubilant Organosys Limited One pot synthesis of citalopram from 5-cyanophthalide
US20050196453A1 (en) * 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
ITMI20040717A1 (it) * 2004-04-09 2004-07-09 Adorkem Technology Spa Procedimento chemo-enzimatico per la preparazione dell'escitalopram
WO2006001877A2 (en) * 2004-04-13 2006-01-05 Myriad Genetics, Inc. Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
WO2005102366A2 (en) * 2004-04-19 2005-11-03 Philip Maxwell Satow Lithium combinations, and uses related thereto
US20050252144A1 (en) * 2004-04-29 2005-11-17 Macdonald Robert A Veneers for walls, retaining walls and the like
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
EP2141156A1 (en) 2004-08-23 2010-01-06 Sun Pharma Global FZE Process for Preparation of Citalopram and Enantiomers
US7989645B2 (en) * 2004-08-23 2011-08-02 Sun Pharma Global Fze Process for preparation of citalopram and enantiomers
CN104922117A (zh) 2005-03-22 2015-09-23 阿泽范药品公司 用于治疗月经前病症的β-内酰氨基链烷酸
WO2006103550A1 (en) * 2005-03-31 2006-10-05 Ranbaxy Laboratories Limited Processes for the preparation of citalopram and its intermediate 5-aminophthalide
EP1879875A1 (en) * 2005-04-22 2008-01-23 Wyeth Crystal forms opf {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
MX2007012936A (es) * 2005-04-22 2008-01-11 Wyeth Corp Derivados de dihidrobenzofurano y usos de los mismos.
JP2008538572A (ja) 2005-04-22 2008-10-30 ワイス ジヒドロベンゾフラン誘導体およびその使用
US7368477B2 (en) 2005-04-22 2008-05-06 Wyeth Benzofuranyl alkanamine derivatives and uses thereof
US7834201B2 (en) 2005-06-22 2010-11-16 H. Lundbeck A/S Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
TWI358407B (en) 2005-06-22 2012-02-21 Lundbeck & Co As H Crystalline base of escitalopram and orodispersibl
SG163588A1 (en) * 2005-07-08 2010-08-30 Braincells Inc Methods for identifying agents and conditions that modulate neurogenesis
US20070015832A1 (en) * 2005-07-14 2007-01-18 Myriad Genetics, Incorporated Methods of treating overactive bladder and urinary incontinence
SI1910346T1 (sl) * 2005-07-19 2019-08-30 Azevan Pharmaceuticals, Inc. Antagonist beta-laktamil fenilalalina, cisteina in serin vasopresina
WO2007014124A2 (en) * 2005-07-22 2007-02-01 Myriad Genetics, Inc. High drug load formulations and dosage forms
US7598255B2 (en) * 2005-08-04 2009-10-06 Janssen Pharmaceutica Nv Pyrimidine compounds as serotonin receptor modulators
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
JP2009515840A (ja) * 2005-11-14 2009-04-16 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムの製造方法
GB0601286D0 (en) 2006-01-23 2006-03-01 Sandoz Ag Asymmetric synthesis
FR2912057B1 (fr) * 2007-02-07 2009-04-17 Sanofi Aventis Sa Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP1991212A1 (en) * 2006-03-08 2008-11-19 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR20080105104A (ko) * 2006-03-24 2008-12-03 와이어쓰 우울증 치료를 위한 신규한 치료학적 병용제
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
CA2651862A1 (en) * 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
WO2008006099A2 (en) * 2006-07-07 2008-01-10 Myriad Genetics, Inc. Treatment of psychiatric disorders
WO2008059514A2 (en) * 2006-07-31 2008-05-22 Cadila Healthcare Limited Process for preparing escitalopram
TW200817003A (en) * 2006-07-31 2008-04-16 Sanofi Aventis Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor
KR20090064418A (ko) * 2006-09-08 2009-06-18 브레인셀즈 인코퍼레이션 4-아실아미노피리딘 유도체 포함 조합물
US20100016274A1 (en) * 2006-09-14 2010-01-21 Koppel Gary A Beta-lactam cannabinoid receptor modulators
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
JP4927497B2 (ja) * 2006-10-25 2012-05-09 株式会社シスコ 無湿乾燥用ホッパー装置
CN100457747C (zh) * 2006-11-21 2009-02-04 浙江大学 抗抑郁药西酞普兰关键中间体5-氰基苯酞的制备工艺
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
US20080171750A1 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation Of Neurogenesis With Use of Modafinil
PT1988086E (pt) 2007-04-23 2012-02-28 Synthon Bv Processo para a resolução de citalopram via o seu composto tartarato de citalopram enriquecido em (s)
CA2685424A1 (en) * 2007-05-18 2008-11-27 Cipla Limited Process for the preparation of escitalopram via desmethylcitalopram, optical resolution and methylation of the s-isomer
US20080312318A1 (en) * 2007-06-14 2008-12-18 Protia, Llc Deuterium-enriched escitalopram
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US8022232B2 (en) * 2007-09-11 2011-09-20 H. Lundbeck A/S Method for manufacture of escitalopram
KR101103118B1 (ko) * 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
US20110034565A1 (en) 2008-04-18 2011-02-10 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
EP2116231A1 (en) 2008-05-07 2009-11-11 Hexal Ag Granulate comprising escitalopram oxalate
US20100087664A1 (en) * 2008-10-07 2010-04-08 Ravindra Vedantham Preparation of citalopram and salts thereof
GR20080100696A (el) 2008-10-23 2010-05-13 Genepharm �.�. Φαρμακοτεχνικη μορφη με βελτιωμενη γευση του φαρμακευτικα αποδεκτου αλατος εσιταλοπραμης
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
HUE028650T2 (en) 2009-10-23 2016-12-28 Janssen Pharmaceutica Nv Disubstituted octahy - dropyrrolo [3,4-c]pyrroles as orexin receptor modulators
AU2011272738B2 (en) 2010-07-01 2015-08-20 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
WO2013081567A1 (en) 2011-12-02 2013-06-06 Mahmut Bilgic Effervescent antipsychotic formulations
WO2013100870A1 (en) 2011-12-02 2013-07-04 Mahmut Bilgic New antipsychotic compositions
WO2013110313A1 (en) * 2012-01-23 2013-08-01 H. Lundbeck A/S Selective allosteric modulators of the serotonin transporter
JP7255967B2 (ja) 2014-03-28 2023-04-11 アゼヴァン ファーマスーティカルズ，インコーポレイテッド 神経変性疾患を治療するための組成物および方法
NZ785827A (en) 2016-03-10 2025-05-02 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
BR112020005107A2 (pt) 2017-09-15 2020-11-03 Azevan Pharmaceuticals, Inc. composições e métodos para o tratamento de lesão cerebral
JP7739256B2 (ja) 2019-07-19 2025-09-16 バイオエクセル セラピューティクス，インコーポレイテッド 鎮静作用のないデクスメデトミジン治療レジメン
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (en:Method) * 1965-03-18

Also Published As

Publication number Publication date
DK143275B (da) 1981-08-03
NO147243B (no) 1982-11-22
SE429551B (sv) 1983-09-12
CA1094087A (en) 1981-01-20
GB1526331A (en) 1978-09-27
NL192451B (nl) 1997-04-01
NL970031I1 (nl) 1997-10-01
NL192451C (nl) 1997-08-04
ZA7757B (en) 1977-11-30
NO147243C (no) 1983-03-02
NL7700244A (nl) 1977-07-18
SE7614201L (sv) 1977-07-15
AU509445B2 (en) 1980-05-15
AU2107377A (en) 1978-07-13
CH626886A5 (en:Method) 1981-12-15
FR2338271A1 (fr) 1977-08-12
JPS6135986B2 (en:Method) 1986-08-15
FI63754B (fi) 1983-04-29
NO770109L (no) 1977-07-15
CH632258A5 (de) 1982-09-30
FR2338271B1 (en:Method) 1982-11-05
DE2657013C2 (de) 1985-11-14
IE44055L (en) 1977-07-14
AT359488B (de) 1980-11-10
DK13177A (da) 1977-07-15
CH632259A5 (de) 1982-09-30
ATA947276A (de) 1980-04-15
NL970031I2 (nl) 1997-10-01
DK143275C (da) 1982-01-18
US4136193A (en) 1979-01-23
DE2657013A1 (de) 1977-07-28
IE44055B1 (en) 1981-07-29
ES454980A1 (es) 1978-04-01
FI63754C (fi) 1983-08-10
JPS52105162A (en) 1977-09-03
BE850401A (fr) 1977-07-14
FI770073A7 (en:Method) 1977-07-15
NO1996001I1 (no) 1996-01-05

Similar Documents

Publication Publication Date Title
US4136193A (en) Anti-depressive substituted 1-dimethylaminopropyl-1-phenyl phthalans
CA2067817C (en) Muscarinic receptor antagonists
JP2637737B2 (ja) 新規な薬剤
HU176709B (en) Process for preparing new trisubstituted 1-phenyl-2,3,4,5-tetrahydro-1h-3-benzazepine derivatives
CS238617B2 (en) Preparation method of new derivatives of cis-phenyl-1,2,3,4-tetra-hydro-1-naphtaleneamines
JPS59106491A (ja) ベンゾキサジン化合物
DE3851925T2 (de) Alkylaminalkoxyphenyl-Derivate, Verfahren zur Verwendung und sie enthaltende Zusammensetzungen.
NO128869B (en:Method)
JPS63502348A (ja) 縮合ベンゾアゼピン
US4540691A (en) Dopamine agonists and use thereof
Cortizo et al. Synthesis and antidopaminergic activity of some 3-(aminomethyl) tetralones as analogs of butyrophenone
JPS61249966A (ja) ベンゾアゼピン誘導体
EP0398326B1 (en) Serotonin antagonist
JPS6040422B2 (ja) 置換１‐アルキルチオフエニル―２，３，４，５―テトラヒドロ―１ｈ―３―ベンズアゼピン化合物
US4616017A (en) Aminohydroxypropoxy substituted aryl compounds
US5330994A (en) Tetrahydropyridine isoxazoline derivatives
JPH08502057A (ja) カルモジュリン拮抗特性を有する複素環式アミン
CA1102807A (en) Piperidylidene derivatives of benzo-fused xanthenes, thioxanthenes and dibenzoxepins
US4923880A (en) 4,5,6,7-Tetrahydroisothiazolo (4,5-c) pyridine derivatives
US5314895A (en) Benzopyran class III antiarrhythmic agents
CA1161857A (en) 3-amino-1-benzoxepin derivatives, their salts and pharmaceutical compositions thereof and process for their preparation
US5102894A (en) Substituted piperidine compounds and their use
US4626542A (en) 4-(5H-dibenzo[a,d]cyclohepten-5-yl)piperidine compounds, pharmaceutical compositions and methods
IE43413B1 (en) Heterocyclic compounds
FI61871B (fi) Analogifoerfarande foer framstaellning av antidepressivt verkande trifluormetylsubstituerade aralkylestrar av alanin